Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Shuxia Qin"'
Publikováno v:
环境与职业医学, Vol 40, Iss 9, Pp 1052-1057 (2023)
BackgroundFew studies have been conducted on the associations of dietary habits with the risks of high normal blood pressure and hypertension in employees of chemical companies in northwest China.ObjectiveTo understand the excess intakes of red meat,
Externí odkaz:
https://doaj.org/article/7af6589061f349719c6e2bd2d1a82fb4
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-11 (2023)
Abstract Background China has one of the highest numbers of liver disease cases in the world, including 6.4 million cirrhosis associated with alcohol-related liver disease (ALD) cases. However, there is still a lack of urgent awareness about the grow
Externí odkaz:
https://doaj.org/article/b41f51cd651d4642be696ed3f090a0db
Autor:
Liting Wang, Ye Peng, Shuxia Qin, Xiaomin Wan, Xiaohui Zeng, Sini Li, Qiao Liu, Chongqing Tan
Publikováno v:
PLoS ONE, Vol 18, Iss 4, p e0279786 (2023)
BackgroundOral multikinase inhibitors and immune checkpoint inhibitors (ICIs) are effective for treating advanced hepatocellular carcinoma (aHCC) but may increase cost. This study compared the cost-effectiveness of oral multikinase inhibitors and ICI
Externí odkaz:
https://doaj.org/article/75b9d97a820e45b3b412c1d1b195b0da
Autor:
Shuxia Qin, Xuehong Wang, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
ObjectiveCurrent guidelines recommend the gastric cancer risk score scale (GCRSS) for screening in gastric cancer (GC) high-risk populations in China. This study aimed to estimate the clinical benefits, harms, cost, and cost-effectiveness of the GCRS
Externí odkaz:
https://doaj.org/article/58573308c77e46d49725851d7af9a67c
Autor:
Meiyu Wu, Shuxia Qin, Liting Wang, Chongqing Tan, Ye Peng, Xiaohui Zeng, Xia Luo, Lidan Yi, Xiaomin Wan
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for adva
Externí odkaz:
https://doaj.org/article/139477effe4744dc93f26ae0c17267d5
Autor:
Meiyu Wu, Shuxia Qin, Liting Wang, Chongqing Tan, Ye Peng, Xiaohui Zeng, Xia Luo, Lidan Yi, Xiaomin Wan
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: The objective of this study is to systematically review the economic evaluations of dapagliflozin in the treatment of patients with heart failure (HF) and describe their general and methodological features.Methods: This systematic review f
Externí odkaz:
https://doaj.org/article/334021fbb88f4dfbaffcaad848b3dce7
Autor:
Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effect
Externí odkaz:
https://doaj.org/article/ecdbc88d68c44d1b846e65a765b81748
Autor:
Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectiveThe use of ipilimumab plus anti-PD-1 has recently been shown to significantly improve the survival of patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy. The study assessed the cost-effectiveness of ipilimumab plus anti-
Externí odkaz:
https://doaj.org/article/a2d7426549cb4e0a9fd8038f8f4f447a
Autor:
Liting Wang, Shuxia Qin, Chongqing Tan, Xiaohui Zeng, Liubao Peng, Ye Peng, Sini Li, Xiaomin Wan
Publikováno v:
Advances in Therapy. 38:4354-4365
Cemiplimab may significantly increase overall survival in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level of at least 50%. Therefore, there is a need to consider the cost-effectiveness of using this therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d95e3f129ad6fe96077d951d941d04
https://doi.org/10.1007/s12325-021-01828-1
https://doi.org/10.1007/s12325-021-01828-1
Autor:
Liubao Peng, Chongqing Tan, Sini Li, Shuxia Qin, Xia Luo, Liting Wang, Xiaomin Wan, Lidan Yi, Qiao Liu, Xiaohui Zeng, Ye Peng
Publikováno v:
Advances in Therapy. 38:3962-3972
The effectiveness of nivolumab plus ipilimumab with two cycles of chemotherapy (NIC) for advanced non-small cell lung cancer (NSCLC) has been demonstrated. We aimed to evaluate the cost-effectiveness of NIC for advanced NSCLC from the US payer perspe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27257e2f565e9feb49a501201375250a
https://doi.org/10.1007/s12325-021-01788-6
https://doi.org/10.1007/s12325-021-01788-6